Giddi Pharma

Giddi Pharma is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of innovative small molecule therapeutics for metabolic diseases and oncology. The company focuses on high-potential targets such as G-protein coupled receptors (GPCRs) and multi-incretin pathways to address unmet needs in type 2 diabetes, obesity, and NASH. Its lead candidate, GD-101, is an oral GPR119 agonist currently undergoing Phase 1 clinical trials. Giddi Pharma is supported by leading venture capital firms including Qiming Venture Partners and Matrix Partners China. By leveraging its expertise in medicinal chemistry and metabolic biology, the company aims to deliver differentiated, patient-friendly oral treatments for chronic conditions.